Aethlon Medical, Inc. (NASDAQ: AEMD) is a leading developer of affinity biofiltrationdevices to treat life-threatening diseases. The company’s lead therapeutic candidate, Aethlon Hemopurifier®, is a first-in-class device that targets the rapid elimination of infectious viruses and cancer-promoting exosomes from the circulatory systems of treated individuals. Hemopurifier therapy is currently being advanced under an FDA-approved clinical study. Additionally, Aethlon provides government contracting services to the Defense Advanced Research Projects Agency related to the development of a biofiltration device to treat sepsis. For more information, visit the company’s website at www.aethlonmedical.com.